LLY

752.36

-0.66%↓

JNJ

151.72

+0.28%↑

UNH

304.64

+4.6%↑

ABBV

183.5

-0.25%↓

NVO

65.84

+2.33%↑

LLY

752.36

-0.66%↓

JNJ

151.72

+0.28%↑

UNH

304.64

+4.6%↑

ABBV

183.5

-0.25%↓

NVO

65.84

+2.33%↑

LLY

752.36

-0.66%↓

JNJ

151.72

+0.28%↑

UNH

304.64

+4.6%↑

ABBV

183.5

-0.25%↓

NVO

65.84

+2.33%↑

LLY

752.36

-0.66%↓

JNJ

151.72

+0.28%↑

UNH

304.64

+4.6%↑

ABBV

183.5

-0.25%↓

NVO

65.84

+2.33%↑

LLY

752.36

-0.66%↓

JNJ

151.72

+0.28%↑

UNH

304.64

+4.6%↑

ABBV

183.5

-0.25%↓

NVO

65.84

+2.33%↑

Search

Maravai LifeSciences Holdings Inc (Class A)

Open

2.09

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.01

Max

2.02

Belangrijke statistieken

By Trading Economics

Inkomsten

53M

-46M

Verkoop

-8.8M

56M

EPS

-0.02

Winstmarge

-82.429

Werknemers

570

EBITDA

127M

-21M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+182.86% upside

Dividenden

By Dow Jones

Volgende Winsten

6 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

108M

774M

Vorige openingsprijs

2.09

Vorige sluitingsprijs

2.09

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

18 mei 2025, 23:47 UTC

Marktinformatie

Nikkei May Trade Rangebound Amid Uncertainty Over U.S. Tariffs -- Market Talk

18 mei 2025, 23:40 UTC

Marktinformatie

Gold Rises Amid Concerns Over U.S. Fiscal Deficit -- Market Talk

18 mei 2025, 18:00 UTC

Winsten

Tax Bill News; Target, Home Depot, and Snowflake Earnings; and More Stock Market News to Watch This Week -- Barrons.com

18 mei 2025, 17:01 UTC

Top Nieuws

GM Is Fighting California on EVs. This Is What It Wants to Overturn and Why. -- Barrons.com

18 mei 2025, 16:20 UTC

Winsten

Tesla Demand Hasn't Rebounded Yet. Watch China This Week. -- Barrons.com

18 mei 2025, 12:09 UTC

Top Nieuws

Trump Sounds Upbeat on Ukraine Cease-Fire as Russia Unleashes Drone Barrage -- WSJ

17 mei 2025, 17:15 UTC

Top Nieuws

Trump Attacks Walmart for Tariff-Related Price Increases -- WSJ

17 mei 2025, 09:30 UTC

Top Nieuws
Winsten

In a Trade War, Walmart Lacks Some of Amazon's Ammunition -- Heard on the Street -- WSJ

17 mei 2025, 08:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

17 mei 2025, 08:20 UTC

Marktinformatie
Winsten

Financial Services Roundup: Market Talk

16 mei 2025, 23:18 UTC

Top Nieuws

U.S. Loses Last Triple-A Credit Rating -- 2nd Update

16 mei 2025, 22:30 UTC

Top Nieuws

U.S. Loses Last Triple-A Credit Rating -- Update

16 mei 2025, 21:56 UTC

Marktinformatie

Fitch Raises Greece's Outlook to Positive From Stable -- Market Talk

16 mei 2025, 21:56 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

16 mei 2025, 21:54 UTC

Top Nieuws

U.S. Loses Last Triple-A Credit Rating -- WSJ

16 mei 2025, 21:22 UTC

Marktinformatie

Moody's Says U.S. Fiscal Performance Likely to Deteriorate -- Market Talk

16 mei 2025, 21:17 UTC

Marktinformatie

Treasury Yields Rise, Dollar Falls After Moody's Cuts U.S. Credit Rating -- Market Talk

16 mei 2025, 21:17 UTC

Top Nieuws

The Score: UnitedHealth, Walmart, Coinbase Global and More Stocks That Moved on the Week's News -- WSJ

16 mei 2025, 21:05 UTC

Marktinformatie

Moody's Downgrades U.S. Credit Rating Due to Deficit, Debts -- Market Talk

16 mei 2025, 20:55 UTC

Acquisities, Fusies, Overnames

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 mei 2025, 20:50 UTC

Marktinformatie
Winsten

Financial Services Roundup: Market Talk

16 mei 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

16 mei 2025, 20:37 UTC

Top Nieuws

Trade Progress Sparks Bullish Week for Wall Street -- WSJ

16 mei 2025, 20:33 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Dick's-Foot Locker Deal Looks Like a Bet on Nike's Turnaround -- Market Talk

16 mei 2025, 20:30 UTC

Acquisities, Fusies, Overnames

Galaxy Digital Begins U.S. Trading as Bitcoin Keeps Powering Ahead -- Barrons.com

16 mei 2025, 20:18 UTC

Top Nieuws

Major U.S. Stock Indexes Rise; U.S. Running Out of Patience for Trade Deals -- WSJ

16 mei 2025, 20:16 UTC

Top Nieuws

Justice Department Wants to Spare Boeing From Guilty Plea Over 737 MAX Charges -- 3rd Update

16 mei 2025, 20:15 UTC

Winsten

Tesla Stock Rises. Even Hedge Fund Sales Can't Keep It Down. -- Barrons.com

16 mei 2025, 20:11 UTC

Acquisities, Fusies, Overnames

Henry Schein: William K. Daniel Joins Board

16 mei 2025, 20:10 UTC

Acquisities, Fusies, Overnames

Henry Schein: Strategic Investment by KKR Completed

Peer Vergelijking

Prijswijziging

Maravai LifeSciences Holdings Inc (Class A) Prognose

Koersdoel

By TipRanks

182.86% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 5.94 USD  182.86%

Hoogste 10 USD

Laagste 2 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Maravai LifeSciences Holdings Inc (Class A) - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

10 ratings

6

Buy

4

Hold

0

Sell

Technische score

By Trading Central

2.02 / 2.115Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

No Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.